



Universiteit  
Leiden  
The Netherlands

## Colorectal cancer screening for average- and high-risk individuals: beyond one-size-fits-all

Breekveldt, E.C.H.

### Citation

Breekveldt, E. C. H. (2024, June 5). *Colorectal cancer screening for average- and high-risk individuals: beyond one-size-fits-all*. Retrieved from <https://hdl.handle.net/1887/3759760>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3759760>


**Note:** To cite this publication please use the final published version (if applicable).



# Part II


Towards personalized colorectal  
cancer screening for average-risk  
individuals in the Netherlands





# Chapter 6

Factors associated with interval colorectal cancer after negative FIT: results of two screening rounds in the Dutch FIT-based CRC screening program



ECH Breekveldt, E Toes-Zoutendijk, HJ van de Schootbrugge-Vandermeer,  
L de Jonge, AI Kooyker, MCW Spaander,  
AJ van Vuuren, FJ van Kemenade, CRB Ramakers, E Dekker,  
ID Nagtegaal, ME van Leerdam, and I Lansdorp-Vogelaar.

## ABSTRACT

The interval colorectal cancer (CRC) rate after negative fecal immunochemical testing (FIT) is an important quality indicator of CRC screening programs.

We analyzed the outcomes of two rounds of the FIT-based CRC screening program in the Netherlands, using data from individuals who participated in FIT-screening from 2014 to 2017. Data of individuals with one prior negative FIT (first round) or two prior negative FITs (first and second round) were included. Outcomes included the incidence of interval CRC in FIT-negative participants ( $<47 \mu\text{g Hb/g feces } [\mu\text{g/g}]$ ), FIT-sensitivity, and the probability of detecting an interval CRC by fecal hemoglobin concentration (f-Hb). FIT-sensitivity was estimated using the detection method and the proportional incidence method (based on expected CRC incidence). Logistic regression analysis was performed to estimate whether f-Hb affects probability of detecting interval CRC, adjusted for sex- and age-differences.

Incidence of interval CRC was 10.4 per 10 000 participants after the first and 9.6 after the second screening round. FIT-sensitivity based on the detection method was 84.4% (95%CI 83.8-85.0) in the first and 73.5% (95% CI 71.8-75.2) in the second screening round. The proportional incidence method resulted in a FIT-sensitivity of 76.4% (95%CI 73.3-79.6) in the first and 79.1% (95%CI 73.7-85.3) in the second screening round. After one negative FIT, participants with f-Hb just below the cut-off ( $>40\text{-}46.9 \mu\text{g/g}$ ) had a higher probability of detecting an interval CRC (OR 16.9; 95%CI: 14.0-20.4) than had participants with unmeasurable f-Hb (0-2.6  $\mu\text{g/g}$ ). After two screening rounds, the odds ratio for interval CRC was 12.0 (95%CI: 7.8-17.6) for participants with f-Hb just below the cut-off compared with participants with unmeasurable f-Hb.

After both screening rounds, the Dutch CRC screening program had a low incidence of interval CRC and an associated high FIT-sensitivity. Our findings suggest there is a potential for further optimizing CRC screening programs with the use of risk-stratified CRC screening based on prior f-Hb.

## INTRODUCTION

Organized colorectal cancer (CRC) screening programs have been adopted widely with the aim to reduce CRC-related mortality. These programs are mostly based on fecal immunochemical testing for occult human hemoglobin (FIT). The quantitative nature of FIT ( $\mu\text{g Hb/g feces}$ ) allows for adjusting the cut-off for a positive test result. Several factors can be considered to determine the optimal cut-off; that is, positivity rate, colonoscopy capacity and sensitivity of FIT for CRC.

The incidence of interval CRCs after a negative FIT may serve to indicate the sensitivity of FIT, based on the occurrence of false-negative FITs. Evaluation of the sensitivity of FIT and the incidence of interval CRC is necessary to assess the quality of the program (1). Besides, it can reveal information on characteristics of interval CRCs that might provide insight on the number of cancers missed in FIT-based screening. Previous research showed that higher fecal Hb (f-Hb) concentrations in prior screening rounds were associated with higher detection of CRC or advanced neoplasia (AN) in subsequent screening rounds, as well as a higher probability of detecting interval CRC after negative FIT (2–8). Still, the small sample sizes in those studies call for validation of this risk factor in larger populations.

In the Netherlands, an organized FIT-based screening program went ahead in 2014, inviting all individuals eligible for screening every two years. The complete target population has been invited from 2019 onwards and participation rates are consistently high (around 72%). A previous study from our group found that the Dutch CRC screening program revealed a low incidence of interval CRC and an associated high sensitivity of FIT after one screening round (5). Only few studies are available on the incidence of interval CRC and sensitivity after multiple screening rounds, especially detailed data on specific screening rounds are scarce (9).

In this study, we evaluated the incidence of interval CRC and sensitivity of FIT within the framework of the FIT-based CRC screening program in the Netherlands, both after one screening round (one prior negative FIT) and after two screening rounds (two prior negative FITs). In addition, we assessed characteristics (i.e., localization and stage distribution) of these interval CRCs, as well as the probability of detecting interval CRC based on f-Hb concentrations at prior screening.

## **METHODS**

### *Dutch national screening program*

In 2014, the Dutch national CRC screening program was introduced, for which all individuals aged 55 to 75 were invited biennially for FIT-based screening (FOB-Gold, Sentinel Diagnostics, Milan, Italy). The program was gradually rolled out by birth cohort. Since 2019, all individuals in the target population (around 4.4 million) have been invited at least once. Those with a positive FIT were referred for colonoscopy; in case of a negative FIT, participants were invited for a second test 24 months later. Initially, a FIT positivity cut-off of 15  $\mu\text{g}$  Hb/g feces was used; this was adjusted to 47  $\mu\text{g}$  Hb/g feces in June 2014. The rationale for this choice has been described previously (10).

### *Data collection*

Real-time data from the Dutch CRC program stored in the national screening information system (ScreenIT) were linked with data from the Netherlands Cancer Registry (NCR). This would enable identifying CRCs diagnosed after a positive and after a negative FIT. Data from the NCR, including complete data on incidence and stage distribution, covered the period from January 1, 2014 to November 1, 2019. To ensure complete follow-up for analyses on interval CRC (24 months), only participants tested between January 1, 2014 and November 1, 2017 were included in the analyses. To maintain homogeneity within groups, only participants tested at the positivity cut-off of 47  $\mu\text{g}$  Hb/g feces that was initiated in June 2014 were included. First screening round participants were defined as participants with one prior negative or positive FIT at the first invitation round. Second screening round participants were defined as participants with one prior negative FIT at the first invitation round and subsequent negative or positive FIT at the second invitation round.

### *Definitions*

A negative FIT was defined as a FIT with f-Hb concentration  $<47$   $\mu\text{g}$  Hb/g feces. A positive FIT was defined as a FIT with f-Hb concentration  $\geq 47$   $\mu\text{g}$  Hb/g feces. Interval CRC was defined as CRC diagnosed after a negative FIT and before invitation to the next screening round, according to the proposed nomenclature by the World Endoscopy Organization (11). For participants who were not eligible for the subsequent screening round because they had reached the upper age limit, interval



CRC was defined as CRC diagnosed within 24 months after a negative FIT. Screening-detected CRC was defined as CRC diagnosed within 180 days after a colonoscopy following a positive FIT. The episode sensitivity of FIT was defined as the percentage of individuals in the screened population who were identified by the FIT and confirmed as truly positive (i.e., having CRC) at colonoscopy. Episode sensitivity reflects the full diagnostic process of CRC screening per screening round (12).

Interval CRC was categorized as right-sided (caecum to transverse colon, C18.0, C18.2-C18.4), left-sided (splenic flexure to rectosigmoid, C18.5-C18.7, C19), rectum (C20), or overlapping and not otherwise specified (NOS; C18.8-C18.9) (13). Appendiceal cancers (C18.1) were excluded from analyses. In case of synchronous CRCs, the CRC with the most advanced stage was included in the analyses. Stage distribution was determined using the effective Tumor, Node, Metastases (TNM)-classification at year of diagnosis (seventh edition in 2014-2016, eighth edition from 2017).

### *Outcomes*

Primary outcomes were the incidence of interval CRC, the episode sensitivity and the probability of detecting interval CRC by f-Hb concentration after the first and second round, respectively. The incidence of interval CRC was calculated by dividing the number of interval CRCs by the total number of participants with a negative FIT in the same screening round, and is presented per 10 000 participants with a negative FIT. Furthermore, we determined the probability of detecting interval CRC by f-Hb concentration, corrected for sex- and age-differences. Secondary outcomes were localization and stage distribution of interval CRCs and screening-detected CRCs diagnosed after the first and second round.

### *Statistical analysis*

We estimated the incidence of interval CRC and episode sensitivity of FIT for CRC after the first and second screening round of the Dutch national CRC screening program. Episode sensitivity was estimated in two ways: through the detection method and the proportional incidence (PI) method. Episode sensitivity according to the detection method was calculated from the number of screening-detected CRCs (SD-CRC) per round divided by the sum of interval CRCs and screening-detected CRCs for that specific round, using the formula: Sensitivity(detection method) =  $\frac{SD-CRC}{IC+SD-CRC}$ .

Episode sensitivity according to the PI method was calculated from the expected CRC incidence extrapolating data from the pre-screening era. A log-linear Poisson model served to estimate the expected CRC incidence from age-specific CRC incidence trends in the Netherlands in the pre-screening era (2009-2013). Based on this estimate, the expected sex- and age-specific CRC incidences for the first (2014-2017) and second (2016-2017) round were calculated. Trends were standardized by sex- and age distributions of the study population. Next, the proportional incidence or rate ratio (RR) of interval CRC (IC) was estimated as the number of interval CRCs divided by the length of the interval multiplied by the expected annual CRC incidence (E) for that specific sex- or age group, using the formula:  $RR = \frac{IC}{\text{Interval length}(\text{years}) \times E}$ . The mean interval length was 1.97 years (23.7 months) in the first round and 1.96 years (23.5 months) in the second round. The episode sensitivity was calculated using the formula: Sensitivity (PI method) = 1 – RR.

The incidence of interval CRC and the sensitivity of FIT are summarized using standard descriptive statistics, displaying the 95% confidence interval (CI). Chi-square testing was performed to compare localization and stage distribution of interval CRCs with screening-detected CRCs after the first and second round, respectively. Calculated p values are two-sided and are considered statistically significant when <.05.

Logistic regression analysis was performed to determine the odds ratio (OR) of interval CRC after the first and after the second round, based on f-Hb concentration, adjusted for sex- and age-differences. Only data of individuals who participated in both rounds were used to determine the number of interval CRCs after the second round. F-Hb concentrations were categorized as: unmeasurable (0-2.6 µg Hb/g feces; below limit of detection), >2.6 to 10 µg Hb/g feces, >10 to 20 µg Hb/g feces, >20 to 30 µg Hb/g feces, >30 to 40 µg Hb/g feces and >40 to 46.9 µg Hb/g feces. Five age categories were defined with respect to interval CRCs after the first round: 55-59, 60-64, 65-69, 70-74 and ≥ 75 years. Complete data on interval CRCs after the second round were available for only three age categories: namely 60-64, 65-69 and ≥70 years.


We evaluated the probability of detecting an interval CRC using multiple models. Model 1 concerned the OR of detecting interval CRC based on f-Hb concentration of participants with a negative FIT at the first round. Model 2 concerned the OR of detecting interval CRC based on the last measured f-Hb concentration of participants with a negative FIT at the second round. Lastly, f-Hb concentrations at both the first and second round of participants with a negative FIT

in both rounds were incorporated (Models 3a-c). These models were variations of model 2. Model 3a included dichotomous (0-2.6 vs. >2.6-46.9 µg Hb/g feces) f-Hb concentrations of the first round as well as categorical f-Hb concentrations of the second round. Model 3b included summed f-Hb concentrations of both rounds, dividing this added value into quantiles. Model 3c included categorical f-Hb concentrations of both rounds, as opposed to only the last f-Hb concentration measured in the second round (Model 2). Goodness-of-fit of the models was determined by comparing Akaike Information Criterion (AIC) scores of the different models.

Data management and analysis were performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).

## RESULTS

The first round included 2,302,711 individuals of whom 2,153,582 (93.5%) had a negative FIT, and 2,256 of the latter had been diagnosed with an interval CRC (Figure 1 and Table 1). Median age of the FIT-negative participants was 67 years (interquartile range [IQR]: 63-73). At the first round, 149,129 (6.5%) participants had a positive FIT, of whom 12,183 had been diagnosed with a screening-detected CRC (Figure 1).



**Figure 1 - Flowchart displaying numbers for first and second round. CRC, colorectal cancer; FIT, fecal immunochemical test; SD-CRC, screening-detected colorectal cancer**

**Table 1 - Characteristics study population**

	First screening round		Second screening round	
	<i>Negative FIT,</i> n (%)	<i>Interval CRC,</i> n (%)	<i>Negative FIT,</i> n (%)	<i>Interval CRC,</i> n (%)
<i>Total</i>	2,153,582	2,256	703,895	675
Men	1,024,314 (47.6)	1,178 (52.2)	334,559 (47.5)	366 (54.2)
Women	1,129,268 (52.4)	1,078 (47.8)	369,336 (52.5)	309 (45.8)
<i>Age distribution</i>				
56-59	336,917 (15.6)	122 (5.4)	-	-
60-64	767,684 (35.6)	594 (26.3)	76,543 (10.9)	46 (6.8)
65-69	626,627 (29.1)	729 (32.3)	532,388 (75.6)	519 (76.9)
70-74	171,944 (8.0)	279 (12.4)	94,964 (13.5)	110 (16.3)
≥75	250,410 (11.6)	532 (23.6)	-	-
<i>Prior f-Hb concentration (µg Hb/g feces)</i>				
Unmeasurable (0-2.6)	1,907,528 (88.7)	1,143 (50.7)	654,010 (92.9)	441 (65.3)
>2.6-10	127,256 (5.9)	324 (14.3)	21,513 (3.1)	69 (10.2)
>10-20	62,479 (2.9)	292 (12.9)	13,305 (1.9)	66 (9.8)
>20-30	26,723 (1.2)	195 (8.6)	6,895 (1.0)	39 (5.8)
>30-40	18,603 (0.9)	181 (8.0)	5,149 (0.7)	35 (5.2)
>40-46.9	10,993 (0.5)	121 (5.4)	3,023 (0.4)	25 (3.7)

Median age in FIT-positive participants was 65 years (IQR: 61-71). The incidence of interval CRCs in participants with a negative FIT was 10.4 per 10,000 (Table 2). The episode sensitivity of FIT was 84.4% (95%CI 83.8-85.0) as determined with the detection method, and 76.4% (95%CI 73.3-79.6) as determined with the PI method (Table 2 and Appendix Table 1).

Table 2 - Incidence of interval CRC after negative FIT and sensitivity of FIT

		Number				Incidence rate/10,000		RR		SENSITIVITY (PI METHOD) (%; 95%CI)	
		Population screened	IC	SDC	IC	SDC	CRC predicted*	IC	SDC/SDC + IC (%; 95%CI)	1-RR	
<b>ROUND 1</b>	<b>Sex</b>										
	Male	1,113,736	1,178	7,584	10.6	68.1	50.6	0.21	86.6 (85.8-87.3)	79.0 (74.7-83.7)	
	Female	1,188,975	1,078	4,599	9.1	38.7	33.1	0.28	81.0 (80.0-82.0)	72.5 (68.3-77.0)	
	<b>Age (yrs)</b>										
	55-59	353,178	122	899	3.5	25.5	17.4	0.20	88.1 (86.1-90.0)	79.9 (66.9-95.4)	
	60-64	813,106	594	3,248	7.3	40.0	29.5	0.25	84.5 (83.4-85.7)	75.3 (69.4-81.6)	
	65-69	673,110	729	3,985	10.8	59.2	46.1	0.23	84.5 (83.5-85.6)	76.6 (71.2-82.3)	
70-74	187,583	279	1,511	14.9	80.6	62.9	0.24	84.4 (82.7-86.1)	76.3 (67.9-85.8)		
≥75	275,734	532	2,540	19.3	92.1	83.5	0.23	82.7 (81.3-84.0)	76.9 (70.6-83.7)		
	<b>Total</b>	<b>2,302,711</b>	<b>2,256</b>	<b>12,183</b>	<b>9.8</b>	<b>52.9</b>	<b>41.6</b>	<b>0.24</b>	<b>84.4 (83.8-85.0)</b>	<b>76.4 (73.3-79.6)</b>	
<b>ROUND 2</b>	<b>Sex</b>										
	Male	334,559	366	1,066	10.9	31.9	56.6	0.19	74.4 (72.2-76.7)	80.7 (72.9-89.4)	
	Female	369,336	299	808	8.1	21.9	36.1	0.22	73.0 (70.4-75.6)	77.5 (69.2-86.8)	
	<b>Age (yrs)</b>										
	60-64	76,542	46	143	6.0	18.7	29.1	0.21	75.7 (69.5-81.8)	79.4 (59.4-106.0)	
	65-69	532,388	519	1,416	9.7	26.6	45.5	0.21	73.2 (71.2-75.2)	78.7 (72.2-85.7)	
	≥70	94,964	110	315	11.6	33.2	62.3	0.19	74.1 (70.0-78.3)	81.4 (67.5-98.1)	
	<b>Total</b>	<b>703,895</b>	<b>675</b>	<b>1,874</b>	<b>9.6</b>	<b>26.6</b>	<b>45.9</b>	<b>0.21</b>	<b>73.5 (71.8-75.2)</b>	<b>79.1 (73.3-85.3)</b>	

Abbreviations: CI, confidence interval; CRC, colorectal cancer; IC, interval colorectal cancer; PI, proportional incidence; RR, rate ratio; SDC, screening-detected colorectal cancer; Yrs, years.


\* Based on expected CRC incidence using Poisson log linear regression to extrapolate CRC incidence data from the pre-screening era. Displayed for the screening interval of 1.97 years in the first round and 1.96 years in the second round.

The second round included 736,921 individuals, of whom 703,895 (95.5%) had a negative FIT, and 675 of the latter had been diagnosed with an interval CRC (Figure 1 and Table 1). Median age of the FIT-negative participants was 67 years (IQR: 66-69). At the second round, 33,026 (4.5%) participants had a positive FIT, of whom 1,874 had been diagnosed with a screening-detected CRC (Figure 1). The median age of the FIT-positive participants was 67 years (IQR: 65-69). The incidence of interval CRC in participants with a negative FIT was 9.6 per 10,000 (Table 2).

After the second round, the episode sensitivity of FIT was 73.5% (95%CI 71.8-75.2) as determined with the detection method and 79.1% (73.3-85.3) as determined with the PI method (Table 2 and Appendix Table 2). The incidence of interval CRC after the first round was significantly higher than after the second round ( $P=0.04$ ). Furthermore, the incidence of interval CRC was significantly higher in men than in women in both the first ( $P=0.003$ ) and second ( $P=0.002$ ) round (Table 1).

#### *Stage distribution and localization*


After both the first and second round, the stage distribution of interval colon cancers was less favorable than that of the screening-detected colon cancers ( $P<0.0001$ , Figure 2A). After the first round, 17.9% of interval colon cancers were assigned stage I, compared with 46.3% of screening-detected colon cancers. By contrast, 28.1% of interval colon cancers were assigned stage IV, compared with 7.2% of screening-detected colon cancers. The same pattern was observed after the second round (Figure 2B). In both rounds, interval colon cancers were more often located right-sided than were the screening-detected colon cancers (50.8% vs. 27.3% in the first round and 54.1% vs. 36.2% in the second round;  $P<0.0001$ , Figure 3A, B).



**Figure 2 - (A) Stage distribution interval and screening-detected cancers after the first round. (B) Stage distribution interval and screening-detected cancers after the second round.**

After both the first and second round, the stage distribution of interval rectal cancers differed from that of screening-detected rectal cancers ( $P < 0.0001$ , Figure 2A, B). After the second round, 26.0% of interval rectal cancers were assigned stage I, vs. 44.0% of screening-detected rectal cancers. By contrast, 15.7% of interval rectal cancers were assigned stage IV, vs. 7.2% of screening-detected rectal cancers. The proportions of cancers diagnosed in the rectum were quite comparable between interval and screening-detected cancers, both in the first round (25.9% vs. 26.1%, respectively) and in the second round (26.5% vs. 28.3%, respectively; Figure 3A, B).






**Figure 3 - (A) Localization interval and screening-detected cancers after the first round. (B) Localization interval and screening-detected cancers after the second round.**

*Association between f-Hb concentration and interval CRC after the first round*

The vast majority (88.7%) of participants with a negative FIT had an unmeasurable f-Hb concentration after the first round (Table 1). With increasing f-Hb concentrations, the corresponding percentage of participants decreased. The probability of detecting an interval CRC increased with increasing f-Hb concentrations and during the period until the next invitation after 24 months (Figure 4A). In participants with the highest f-Hb concentration just below cut-off (>40-46.9  $\mu\text{g Hb/g feces}$ ), 1.08% had an interval CRC detected at 24 months, as opposed to 0.06% in those with an unmeasurable f-Hb concentration (Figure 4A). After the first round, participants in the category with the highest f-Hb concentrations (>40-46.9  $\mu\text{g Hb/g feces}$ ) had an OR of 16.9 (95% CI 13.9-20.3) for detection of interval CRC

compared with participants with unmeasurable f-Hb concentration, when adjusted for sex- and age-differences (Model 1; Table 3).



**Figure 4 - (A) Probability of detecting interval CRCs after the first round by subgroups of f-Hb concentrations. (B) Probability of detecting interval CRCs after the second round by subgroups of f-Hb concentrations.**

**Table 3 – Multivariable logistic regression analysis: association between f-Hb concentration and interval CRC in the first and second round, adjusted for sex- and age-differences**

	<b>First screening round (Model 1) Odds ratio, 95%CI</b>	<b>Second screening round (Model 2) Odds ratio, 95%CI</b>
<b>Sex</b>		
Men	REF	REF
Women	0.9 (0.9-1.0)	0.8 (0.7-1.0)
<b>Age category*</b>		
56-60	REF	-
60-64	1.8(1.5-2.2)	REF
65-69	2.4(2.0-2.9)	1.6(1.2-2.1)
70-74	3.8(3.0-4.7)	1.8(1.3-2.6)
≥75	4.3(4.6-5.3)	-
<b>Prior f-Hb concentration (µg Hb/g feces)*</b>		
Unmeasurable (0-2.6)	REF	REF
>2.6-10	4.0 (3.5-4.5)	4.7 (3.6-6.0)
>10-20	7.2(6.3-8.1)	7.2 (5.5-9.3)
>20-30	11.1(9.5-12.9)	8.2 (5.8-11.2)
>30-40	14.9 (12.7-17.4)	9.9 (6.9-13.7)
>40-46.9	16.9(13.9-20.3)	12.0 (7.8-17.6)

Abbreviations: 95% CI, 95% confidence interval; CRC, colorectal cancer; f-Hb, fecal hemoglobin.

\* P <0.05.

### *Association between f-Hb concentration and interval CRC after the second round*

After the second round, again, most participants with a negative FIT had an unmeasurable f-Hb concentration (92.9%, Table 1). The probability of detecting an interval CRC increased with higher f-Hb concentrations and during the period until the next invitation (Figure 4B). In participants with the highest f-Hb concentration just below cut-off (>40-46.9 µg Hb/g feces), 0.83% had an interval CRC detected at 24 months, as opposed to 0.07% in participants with unmeasurable f-Hb concentrations (Figure 4B).

Similar to the first round, multivariable analysis showed a strong correlation between f-Hb concentration and detection of interval CRC after the second round, when adjusted for sex- and age-differences. Participants with the highest f-Hb concentrations (>40-46.9 µg Hb/g feces) had an OR of

12.0 (95% CI 7.8-17.6) for detection of interval CRC compared with participants with unmeasurable f-Hb concentrations (Model 2; Table 3).

Lastly, we compared different models for estimating the probability of detecting an interval CRC after the second round. These models were a variation of model 2 and took into account f-Hb concentrations of the first round as well. Model 3a included dichotomous f-Hb concentrations of the first round and categorical f-Hb concentrations of the second round (AIC: 10,236.53, Appendix Table 3). Model 3b included summed f-Hb concentrations of both rounds, dividing this added value into quantiles (AIC: 10,268.59, Appendix Table 4). The model that discriminated best was the one that included categorical f-Hb concentrations of the first and second round separately (Model 3c, AIC: 10,232.83, Table 4).

This model performed better than the model taking into account only the f-Hb concentration measured in the second round (AIC: 10,275.10). Thus, the goodness-of-fit of the model incorporating f-Hb concentrations of two consecutive rounds (model 3c) was superior to the goodness-of-fit of the model only incorporating the last measured f-Hb concentration (model 2).

## DISCUSSION

This study evaluated the incidence of interval CRC and sensitivity of FIT after the first and the second screening round of the Dutch national FIT-based CRC screening program. In both rounds, the incidence of interval CRC was low, whereas the sensitivity of FIT was high. Compared with screening-detected CRC, interval CRC was more often diagnosed in men, more often at an advanced stage, and was more often located at the right side of the colon. Importantly, the higher the f-Hb concentration, the higher the odds of detection of interval CRC, both after the first and the second round. The goodness-of-fit of the used model increased when f-Hb concentrations of both rounds (as opposed to only the last measured f-Hb concentration) were included to estimate the OR of interval CRC after the second round. This would suggest that not only the last measured f-Hb concentration but also the prior screening history might be predictive for the detection of interval CRC.

Our results showed a high sensitivity of FIT in the Dutch CRC screening program. A systematic review on FIT-sensitivity found a pooled sensitivity of FIT for CRC of 0.71 (95%CI 0.56-0.83) in 12 studies that used a positivity cut-off for FIT of  $>20 \mu\text{g Hb/g feces}$  (14). The measured FIT-sensitivity in our study was slightly higher, but from that review it was not clear which round was assessed in the various studies. Furthermore, the sensitivity of FIT was calculated with a screening colonoscopy as the gold standard (i.e., reference), whereas we have approximated the sensitivity from the interval CRC rate. The latter approach could result, however, in an over- or underestimation of the actual FIT-sensitivity. Overestimation might occur when prevalent early-stage CRCs went unrecognized as interval CRCs during the relevant time period. Underestimation might occur when interval CRCs actually were advanced adenomas at the time of prior FIT, which also impacts sensitivity estimates.

We approximated the FIT-sensitivity in two ways: with the detection method and the proportional incidence method. The decrease in sensitivity over two rounds found with the detection method can be explained by the first round being a prevalence round, and subsequent rounds are incidence rounds. The sensitivity was estimated by dividing the number of screening-detected CRCs by the sum of interval CRCs and screening-detected CRCs. In

the first round, prevalent cancers will most likely be detected through screening. Because most of the prevalent cancers will be diagnosed after the first round and the number of interval cancers detected will remain stable, we might expect a plateau phase in sensitivity of FIT after multiple screening rounds. This phenomenon has been described in several previous studies (9,15,16).

The proportional incidence method allows for comparisons between programs, as it makes use of data on the (expected) background incidence of CRC in the target population. Moreover, the resulting estimate is unaffected by the effect of overdiagnosis. A very important caveat when calculating expected trends based on the CRC incidence in the pre-screening era is that time trends cannot be taken into account. This phenomenon may lead to overestimation of the protective effect of the FIT. Still, our results testify to the satisfactory performance of the FIT in the Dutch CRC screening program. When calculating the sensitivity of FIT in a CRC screening program, there are a few caveats worth mentioning. From a screening program perspective, estimating sensitivity per screening round ensures that we can obtain the relevant measure of FIT sensitivity: CRC detection before clinical manifestation. Nevertheless, from a screening participant's point of view, one could argue that individuals with a screen-detected CRC at the second screening round and a negative FIT at the first screening round are false negative test results and that this should be taken into account when estimating the sensitivity of the FIT in the first screening round. However, it is unknown what percentage of these screen-detected CRCs were actually missed cancers in earlier screening, since colonoscopy is not performed in FIT-negative individuals. Furthermore, it is unclear what percentage of screen-detected CRCs should be included in this calculation, as it is unlikely that early-stage screen-detected CRCs were missed CRCs in the previous screening round. When advanced-stage screen-detected CRCs in the subsequent round are included in the calculation, this would (somewhat) reduce the FIT sensitivity. The evaluation of FIT-based screening programs does not yet take this phenomenon into account when estimating the sensitivity of FIT (15,17–21). Cancer screening researchers should discuss and reach consensus on the calculation of FIT

sensitivity, similar to the consensus statement on post-colonoscopy cancers (22).

The finding that interval CRCs were more often diagnosed at the right side of the colon seems to underline the hypothesis that the FIT-sensitivity is higher for left-sided cancers and that right-sided lesions are more frequently missed by FIT. A reason for this could be that approximately 75% of advanced serrated lesions are right-sided, and tend to bleed less than do (advanced) adenomas. Furthermore, they are hypothesized to progress much faster into carcinoma than do adenomas once dysplasia has established (23,24). A second hypothesis could be the degradation of hemoglobin, which may occur at a greater extent in right-sided lesions, leading to lower concentrations of fecal hemoglobin. Unexpectedly, in the present study the proportion of rectal cancers diagnosed was similar for interval and screening-detected cancers. Further research is necessary to find the reason for these missed rectal cancers.

Previous f-Hb concentrations appear to have a greater predictive value for developing AN in future rounds than, for example, age, lifestyle or family history (4,25–27). In this study, we used different models to estimate the probability of detecting an interval CRC after both rounds. We found that the model that incorporated f-Hb concentrations of both the first and second round performed better to estimate probability of detecting an interval CRC after the second round than did the model that included only the last measured f-Hb concentration after the second round. This indeed goes to show that prior screening history could be predictive for detection of interval CRC. When we assessed the predictive value of the variation in both f-Hb concentrations (i.e., the delta) on the probability of detecting interval CRCs, this model was not significant. We expected a higher association between this delta and detection of interval CRC after the second round. However, when information on CRCs of multiple screening rounds becomes available, the prior screening history—that is, the variation in f-Hb concentrations—could allow identifying individuals at highest probability of detecting an interval CRC with the use of more advanced statistics such as a (linear) mixed model.

Although the incidence of interval CRC was low after both rounds, the largest proportion of interval CRCs was diagnosed at an advanced stage. As

these are associated with higher morbidity and mortality, the importance of preventing these interval CRCs is self-evident. Of note, we found substantial differences in the probability of detecting an interval CRC by f-Hb concentration, like in recent studies from Spain and Italy (8,28). There are several options to address participants at highest probability of developing an interval CRC, hereby increasing benefits of the screening program. In case of a history of multiple previous f-Hb concentrations just below the cut-off, they can be offered colonoscopy. Alternatively, the screening interval can be shortened, thereby intensifying FIT-based screening. Clearly, the first option would require additional colonoscopy capacity. In our study, this would require approximately 10% additional colonoscopy capacity per screening round. Both options warrant close consultation with public health officials, while considering that information on multiple screening rounds should be available to make well-balanced decisions on these strategies, especially with intensifying FIT-screening. In the Netherlands, every year approximately two million individuals were invited to participate in the screening program, of whom about 72% participated (29). Around 95% of them had a negative FIT. In this study, we found that only 10% of all participants with a negative FIT had detectable f-Hb concentrations below the cut-off ( $>2.6\text{-}47\ \mu\text{g Hb/g feces}$ ). Importantly, around 50% of all interval CRCs had been diagnosed in this small population. The associated higher probability of detecting an interval CRC in this small population, coupled with the large proportion of participants with a negative FIT and an unmeasurable f-Hb concentration, indicates possibilities for risk-stratified CRC screening. Such a program could improve the harm-benefit balance, increase the yield of AN (in terms of detection rate and positive predictive value) and imply a lower burden of screening for participants at low risk. Still, factors such as acceptability, participation and use of resources need to be considered as well (30).

We reported on probability of detecting interval CRCs for different categories of f-Hb concentration, thus making these data generalizable to programs using other cut-offs. Obviously, the generalizability is highly dependent on the set-up of the program (i.e., population-based vs. opportunistic screening). Another important strength of this study is the large sample size, enabling us to combine essential information on interval CRC in



a national, organized screening program. The main limitation of this study is that we could incorporate only data from two rounds. This is due to a data acquisition delay of information on CRC, such as the stage distribution. We hope that after having analyzed information from multiple rounds of FIT screening we will be able to identify which and how patterns of f-Hb concentrations influence the probability of detecting interval CRCs.

To conclude, we found that the CRC screening program in the Netherlands has a low incidence of interval CRC and an associated high FIT-sensitivity, after one and two consecutive screening rounds. The probability of detecting interval CRCs increased with increasing fecal hemoglobin concentrations. Our findings suggest there is a potential for further optimizing CRC screening programs with the use of risk-stratified CRC screening based on prior fecal hemoglobin concentrations.

## REFERENCES

1. Moss S, Ancelle-Park R, Brenner H. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Evaluation and interpretation of screening outcomes. *Endoscopy*. 2012;44(SUPPL3).
2. Grobbee EJ, Schreuders EH, Hansen BE, Bruno MJ, Lansdorp-Vogelaar I, Spaander MCW, et al. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. *Gastroenterology*. 2017;153(5):1251-1259.e2.
3. Liao CS, Lin YM, Chang HC, Chen YH, Chong LW, Chen CH, et al. Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia. *World J Gastroenterol*. 2013;19(45):8366–72.
4. van de Veerdonk W, Van Hal G, Peeters M, De Brabander I, Silversmit G, Hoeck S. Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme. *Cancer Epidemiol* [Internet]. 2018;56(June):90–6. Available from: <https://doi.org/10.1016/j.canep.2018.07.015>
5. Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MCW, Opstal-van Winden AWJ, Ramakers C, et al. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. *Clinical Gastroenterology and Hepatology*. 2020;18(7):1493–500.
6. Chiu SYH, Chuang SL, Chen SLS, Yen AMF, Fann JCY, Chang DC, et al. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: Analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. *Gut*. 2017;66(2):293–300.
7. Digby J, Fraser CG, Carey FA, Diament RH, Balsitis M, Steele RJC. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. *J Med Screen*. 2017;24(2):62–8.
8. Senore C, Zappa M, Campari C, Crotta S, Armaroli P, Arrigoni A, et al. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy. *Gut*. 2020;69(3):523–30.
9. Wieten E, Schreuders EH, Grobbee EJ, Nieboer D, Bramer WM, Lansdorp-Vogelaar I, et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: A systematic review and meta-analysis. *Gut*. 2019;68(5):873–81.
10. Kooyker AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, Spaander MCW, Buskermolen M, van Vuuren HJ, et al. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening. *Int J Cancer*. 2020;147(4):1098–106.
11. Sanduleanu S, Le Clercq CMC, Dekker E, Meijer GA, Rabeneck L, Rutter MD, et al. Definition and taxonomy of interval colorectal cancers: A proposal for standardising nomenclature. *Gut*. 2015;64(8):1257–67.
12. Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. *J Med Screen*. 2007;14(4):174–7.
13. D'Souza N, de Neree tot Babberich MPM, d'Hoore A, Tiret E, Xynos E, Beets-Tan RGH, et al. Definition of the rectum: An International, expert-based Delphi consensus. *Ann Surg*. 2019;270(6):955–9.
14. Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced

- adenomatous polyps: A systematic review and meta-analysis. *Ann Intern Med.* 2019;170(5):319–29.
15. Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: A retrospective cohort study. *Ann Intern Med.* 2016;164(7):456–63.
  16. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of Fecal Immunochemical Tests for Colorectal Cancer: Systematic Review and Meta-analysis. *Ann Intern Med.* 2014;160:171–81.
  17. Zorzi M, Hassan C, Senore C, Capodaglio G, Turrin A, Narne E, et al. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme. *J Med Screen.* 2020;
  18. Ribbing Wilén H, Saraste D, Blom J. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test. *J Med Screen.* 2022;
  19. Mlakar DN, Bric TK, Skrjanec AL, Krajc M. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme. *Radiol Oncol.* 2018;52(4):413–21.
  20. van de Veerdonk W, Hoeck S, Peeters M, Van Hal G, Francart J, De Brabander I. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme. *United European Gastroenterol J.* 2020;8(2):185–94.
  21. Niedermaier T, Tikk K, Gies A, Bieck S, Brenner H. Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location. *Clinical Gastroenterology and Hepatology* [Internet]. 2020;18(13):2920-2928.e6. Available from: <https://doi.org/10.1016/j.cgh.2020.01.025>
  22. Rutter MD, Beintaris I, Valori R, Chiu HM, Corley DA, Cuatrecasas M, et al. World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. *Gastroenterology* [Internet]. 2018;155(3):909-925.e3. Available from: <https://doi.org/10.1053/j.gastro.2018.05.038>
  23. Ijspeert JEG, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. *Nat Rev Gastroenterol Hepatol.* 2015;12(7):401–9.
  24. Desai M, Anderson JC, Kaminski M, Thoguluva Chandrasekar V, Fathallah J, Hassan C, et al. Sessile serrated lesion detection rates during average risk screening colonoscopy: A systematic review and meta-analysis of the published literature. *Endosc Int Open.* 2021;09(04):E610–20.
  25. Auge JM, Pellise M, Escudero JM, Hernandez C, Andreu M, Grau J, et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. *Gastroenterology* [Internet]. 2014;147(3):628-636.e1. Available from: <http://dx.doi.org/10.1053/j.gastro.2014.06.008>
  26. Jeon J, Du M, Schoen RE, Hoffmeister M, Newcomb PA, Berndt SI, et al. Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. *Gastroenterology.* 2018;154(8):2152-2164.e19.
  27. Usher-Smith JA, Harshfield A, Saunders CL, Sharp SJ, Emery J, Walter FM, et al. External validation of risk prediction models for incident colorectal cancer using UK Biobank. *Br J Cancer* [Internet]. 2018;118(5):750–9. Available from: <http://dx.doi.org/10.1038/bjc.2017.463>

28. Buron A, Román M, Augé JM, Macià F, Grau J, Sala M, et al. Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program. *Eur J Cancer*. 2019;107:53–9.
29. National Institute for Public Health and the Environment. Monitoring and Evaluation of the Colorectal Cancer Screening Programme. [Internet]. Available from: <https://www.rivm.nl/en/national-monitoring-of-colorectal-cancer-screening-programme>.
30. Lansdorp-Vogelaar I, Meester R, de Jonge L, Buron A, Haug U, Senore C. Risk-stratified strategies in population screening for colorectal cancer. *Int J Cancer*. 2022;150(3):397–405.

## APPENDIX

Table 1 - Incidence of interval CRC after negative FIT and sensitivity of FIT after the first screening round

YEAR	SEX	NUMBER				INCIDENCE RATE/10,000			RR	SENSITIVITY (DETECTION METHOD) (%; 95%CI)	SENSITIVITY (PI METHOD) (%; 95%CI)
		POPULATION SCREENED	IC	SDC	IC	IC	SDC	CRC PREDICTED*			
											1-RR
2014	Male	1,113,736	1,178	7,584	10.6	68.1	50.6	0.21	86.6 (85.8-87.3)	79.0 (74.7-83.7)	
2015		149,000	173	1,184	11.6	79.5	61.4	0.19	87.3 (85.5-89.0)	81.1 (69.9-94.1)	
2016		392,748	442	2,813	11.3	71.6	51.8	0.22	86.4 (85.2-87.6)	78.2 (71.2-85.8)	
2017		335,548	340	2,268	10.1	67.6	49.2	0.21	87.0 (85.7-88.3)	79.5 (71.5-88.4)	
		236,440	223	1,319	9.4	55.8	43.7	0.22	85.5 (83.8-87.3)	78.5 (68.8-89.5)	
2014	Female	1,188,975	1,078	4,599	9.1	38.7	33.1	0.28	81.0 (80.0-82.0)	72.5 (68.3-77.0)	
2015		155,816	192	705	12.3	45.2	40.1	0.31	78.6 (75.9-81.3)	69.4 (60.2-79.9)	
2016		415,218	400	1,704	9.6	41.0	33.9	0.28	81.0 (79.3-82.7)	71.7 (65.0-79.1)	
2017		359,594	333	1,357	9.3	37.7	32.4	0.29	80.3 (78.4-82.2)	71.3 (64.0-79.4)	
		258,347	163	833	6.3	32.2	28.5	0.22	83.6 (81.3-85.9)	77.9 (66.8-90.8)	
	AGE YRS)										
2014**	55-59	353,178	122	899	3.5	25.5	17.4	0.20	88.1 (86.1-90.0)	79.9 (66.9-95.4)	
2015**											
2016		131,000	54	351	4.1	26.8	17.5	0.23	86.7 (83.4-90.0)	76.6 (58.6-100.0)	
2017		222,177	68	548	3.1	24.7	17.3	0.18	89.0 (86.5-91.4)	82.1 (64.7-104.1)	
2014	60-64	813,106	594	3,248	7.3	40.0	29.5	0.25	84.5 (83.4-85.7)	75.3 (69.4-81.6)	
2015		65,329	54	289	8.3	44.2	29.8	0.28	84.3 (80.4-88.1)	72.1 (55.2-94.2)	
2016		307,754	219	1,298	7.1	42.2	29.6	0.24	85.6 (83.8-87.3)	76.0 (66.5-86.7)	
2017		306,822	242	1,224	7.9	39.9	29.4	0.27	83.5 (81.6-85.4)	73.2 (64.5-83.0)	
		133,201	79	437	5.9	32.8	29.3	0.20	84.7 (81.6-87.8)	79.9 (64.1-99.6)	
2014	65-69	673,110	729	3,985	10.8	59.2	46.1	0.23	84.5 (83.5-85.6)	76.6 (71.2-82.3)	
2015		174,659	177	989	10.1	56.6	46.2	0.22	84.8 (82.8-86.9)	78.2 (67.4-90.6)	
		434,841	488	2,580	11.2	59.3	46.1	0.24	84.1 (82.8-85.4)	75.7 (69.3-82.7)	

2016		60,976	63	404	10.3	66.3	45.9	0.22	86.5 (83.4-89.6)	77.6 (60.6-99.3)
2017**	<b>70-74</b>	<b>187,583</b>	<b>279</b>	<b>1,511</b>	<b>14.9</b>	<b>80.6</b>	<b>62.9</b>	<b>0.24</b>	<b>84.4 (82.7-86.1)</b>	<b>76.3 (67.9-85.8)</b>
2014**		110,092	159	886	14.4	80.5	63.0	0.23	84.8 (82.6-87.0)	77.1 (66.0-90.1)
2015**		77,490	120	625	15.5	80.7	62.9	0.25	83.9 (81.3-86.5)	75.4 (63.0-90.1)
2016	<b>≥75</b>	<b>275,734</b>	<b>532</b>	<b>2,540</b>	<b>19.3</b>	<b>92.1</b>	<b>83.5</b>	<b>0.23</b>	<b>82.7 (81.3-84.0)</b>	<b>76.9 (70.6-83.7)</b>
2017		64,828	124	611	18.1	94.2	82.7	0.22	83.1 (80.4-85.8)	78.1 (65.5-93.2)
2014		65,369	135	639	20.7	97.8	83.3	0.25	82.6 (79.9-85.2)	75.2 (63.5-89.0)
2015		86,252	155	760	18.0	88.1	83.9	0.21	83.1 (80.6-85.5)	78.5 (67.1-92.0)
2016		59,285	118	530	19.9	89.4	84.0	0.24	81.8 (78.8-84.8)	76.3 (63.7-91.4)
2017	<b>TOTAL</b>	<b>2,302,711</b>	<b>2,256</b>	<b>12,183</b>	<b>9.8</b>	<b>52.9</b>	<b>41.6</b>	<b>0.24</b>	<b>84.4 (83.8-85.0)</b>	<b>76.4 (73.3-79.6)</b>

Abbreviations: IC: interval colorectal cancer. SDC: screening-detected colorectal cancer. CRC: colorectal cancer. RR: rate ratio. CI: confidence interval. PI: proportional incidence. Yrs: years.

\* based on expected CRC incidence using Poisson log linear regression to extrapolate CRC incidence data from the pre-screening era. Displayed for the screening interval of 1.97 years in the first round and 1.96 years in the second round.

\*\*too few people screened/too few cancers for displaying/significance.

Table 2 - Incidence of interval CRC after negative FIT and sensitivity of FIT after the second screening round

YEAR	SEX	NUMBER		INCIDENCE RATE/10,000		RR	SENSITIVITY (DETECTION METHOD) (%; 95%CI)	SENSITIVITY (PI METHOD) (%; 95%CI)	
		POPULATION SCREENED	IC	SDC	IC				SDC
2016	Male	334,559	366	1,066	10.9	31.9	56.6	74.4 (72.2-76.7)	80.7 (72.9-89.4)
		98,273	125	332	12.7	33.8	55.5	72.6 (68.6-76.7)	77.1 (64.7-91.9)
2017		236,286	241	734	10.2	31.1	57.0	75.3 (72.6-78.0)	82.1 (72.4-93.2)
2016	Female	369,336	299	808	8.1	21.9	36.1	73.0 (70.4-75.6)	77.5 (69.2-86.8)
		105,951	93	220	8.8	20.8	36.0	70.3 (65.2-75.4)	75.5 (61.6-92.6)
2017		263,385	216	588	8.2	22.3	36.1	73.1 (70.1-76.2)	77.3 (67.6-88.3)
2016**	AGE YRS)	76,542	46	143	6.0	18.7	29.1	75.7 (69.5-81.8)	79.4 (59.4-106.0)
		74,517	44	142	5.9	19.1	29.1	76.3 (70.2-82.5)	79.7 (59.3-107.1)
2016	65-69	532,388	519	1,416	9.7	26.6	45.5	73.2 (71.2-75.2)	78.7 (72.2-85.7)
		202,190	216	551	10.7	27.3	45.7	71.8 (68.7-75.0)	76.6 (67.0-87.5)
2017		330,198	303	865	9.2	26.2	45.4	74.1 (71.5-76.6)	79.7 (71.2-89.2)
2016**	≥70	94,964	110	315	11.6	33.2	62.3	74.1 (70.0-78.3)	81.4 (67.5-98.1)
		94,955	110	315	11.6	33.2	62.3	74.1 (70.0-78.3)	81.4 (67.5-98.1)
2017		703,895	675	1,874	9.6	26.6	45.9	73.5 (71.8-75.2)	79.1 (73.3-85.3)

Abbreviations: IC: interval colorectal cancer; SDC: screen-detected colorectal cancer; CRC: colorectal cancer; RR: rate ratio; CI: confidence interval; PI: proportional incidence.

Yrs: years.

\* based on expected CRC incidence using Poisson log linear regression to extrapolate CRC incidence data from the pre-screening era. Displayed for the screening interval of 1.97 years in the first round and 1.96 years in the second round.

\*\*too few people screened/too few cancers for displaying/significance.

**Table 3 - Multivariable logistic regression analysis: association between dichotomous f-Hb concentrations in the first screening round, f-Hb concentration in the second round, and interval CRC in the 2nd screening round, adjusted for sex- and age-differences (Model 3a)**

	<b>Odds Ratio, 95% CI</b>
<b>Sex</b>	
Men	REF
Women	0.9(0.7-1.0)
<b>Age category</b>	
60-64	REF
65-69	1.5(1.2-2.1)
≥70	1.8(1.3-2.5)
<b>F-Hb concentration round 1 (µg Hb/g feces)</b>	
Unmeasurable (0-2.6)	REF
>2.6-46.9	1.8 (1.5-2.1)
<b>F-Hb concentration round 2 (µg Hb/g feces)</b>	
Unmeasurable (0-2.6)	REF
>2.6-10	3.9(3.0-5.1)
>10-20	6.0(4.5-7.7)
>20-30	6.7(4.7-9.3)
>30-40	8.1 (5.6-11.3)
>40-46.9	9.7(6.3-14.4)

Abbreviations: 95% CI = 95% Confidence interval. f-Hb = fecal hemoglobin.



**Table 4 - Multivariable logistic regression analysis: association between summed f-Hb concentrations from the first and second round (quantiles), and interval CRC in the 2nd screening round, adjusted for sex- and age-differences (Model 3b)**

	<b>Odds Ratio, 95% CI</b>
<b>Sex</b>	
Men	REF
Women	0.9 (0.8-1.0)
<b>Age category</b>	
60-64	REF
65-69	1.4 (1.2-1.7)
≥70	1.5 (1.1-1.9)
<b>Summed f-Hb concentration round 1 + round 2, quantiles (µg Hb/g feces)</b>	
Unmeasurable (0-2.6)	REF
1st quantile	1.9 (1.4-2.7)
2nd quantile	2.7 (2.0-3.6)
3rd quantile	5.2 (4.2-6.5)
4rd quantile	8.3 (6.9-10.0)

Abbreviations: 95% CI = 95% Confidence interval. f-Hb = fecal hemoglobin.